miR-19b-1在结直肠癌中的研究进展  

The advance of miR⁃19b⁃1 in colorectal cancer

作　　者：梁琳君 崔勇 LIANG Linjun;CUI Yong(Department of Oncology,Shenzhen Qianhai Shekou Free Trade Zone Hospital,Shenzhen,Guangdong,China,515100)

机构地区：[1]深圳市前海蛇口自贸区医院肿瘤科,广东深圳515100

出　　处：《分子诊断与治疗杂志》2023年第6期1091-1094,共4页Journal of Molecular Diagnostics and Therapy

基　　金：深圳市南山区技术研发项目(2020137)。

摘　　要：结直肠癌是一种发病率高、死亡率高的恶性消化道肿瘤。早期筛查及早期诊断有助于提高结直肠癌患者的远期预后。微小RNA参与多种恶性肿瘤的发生、发展过程,在结直肠癌中具有特异性表达谱、结构稳定且易于检测的特点,有望成为肿瘤筛查和早期诊断的分子标记物。miR-19b-1靶向多基因、多通路参与结直肠癌的疾病过程,并与结直肠癌的临床病理特征、患者预后密切相关,是结直肠癌潜在的肿瘤标记物。因此,本文就miR-19-1在结直肠癌发生发展中的作用及其临床研究进展进行系统综述。Colorectal cancer is a malignant gastrointestinal tumor with high morbidity and mortality.Early screening and early diagnosis can improve the long⁃term prognosis of patients with colorectal cancer.MicroRNAs are involved in the regulation of tumorigenesis and development.They have specific expression profiles,stable structures,and easy detection in a variety of malignant tumors including colorectal cancer.Previous studies have found that miR⁃19b⁃1 targets multiple genes and multiple pathways to participate in the disease process of colorectal cancer,and is related to the clinicopathological features and prognosis of colorectal cancer.Thus,miR⁃19b⁃1 is considered to be a potential tumor marker for colorectal cancer.This article reviews the role of miR⁃19b⁃1 in the development of colorectal cancer and its clinical research progress.

关 键 词：结直肠癌 微小RNA miR-19b-1 

分 类 号：R735.34[医药卫生—肿瘤]